These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8824355)

  • 1. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
    Scher RM; Kosierowski R; Lusch C; Alexander R; Fox S; Redei I; Green F; Raskay B; Amfoh K; Engstrom PF; O'Dwyer PJ
    Invest New Drugs; 1996; 13(4):347-54. PubMed ID: 8824355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.
    Stevenson JP; Scher RM; Kosierowski R; Fox SC; Simmonds M; Yao KS; Green F; Broom C; Fields SZ; Krebs JB; O'Dwyer PJ
    Eur J Cancer; 1998 Aug; 34(9):1358-62. PubMed ID: 9849417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of topotecan in patients with previously untreated pancreatic cancer.
    O'Reilly S; Donehower RC; Rowinsky EK; Ord S; Grochow LB
    Anticancer Drugs; 1996 Jun; 7(4):410-4. PubMed ID: 8826609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
    Hudes GR; Kosierowski R; Greenberg R; Ramsey HE; Fox SC; Ozols RF; McAleer CA; Giantonio BJ
    Invest New Drugs; 1995; 13(3):235-40. PubMed ID: 8729952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
    Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and clinical pharmacokinetic/pharmacodynamic basis for lack of efficacy of 21-day continuous topotecan in patients with untreated advanced adenocarcinoma of the pancreas.
    Mans DR; Di Leone L; Ferrary Caldas AP; Maino M; Almeida L; Cancela AI; Grivicich I; Brondani da Rocha A; Schwartsmann G
    Tumori; 2000; 86(6):458-64. PubMed ID: 11218186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of topotecan in metastatic non-small-cell lung cancer.
    Lynch TJ; Kalish L; Strauss G; Elias A; Skarin A; Shulman LN; Posner M; Frei E
    J Clin Oncol; 1994 Feb; 12(2):347-52. PubMed ID: 8113842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
    Perez-Soler R; Fossella FV; Glisson BS; Lee JS; Murphy WK; Shin DM; Kemp BL; Lee JJ; Kane J; Robinson RA; Lippman SM; Kurie JM; Huber MH; Raber MN; Hong WK
    J Clin Oncol; 1996 Feb; 14(2):503-13. PubMed ID: 8636764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
    Kudelka AP; Tresukosol D; Edwards CL; Freedman RS; Levenback C; Chantarawiroj P; Gonzalez de Leon C; Kim EE; Madden T; Wallin B; Hord M; Verschraegen C; Raber M; Kavanagh JJ
    J Clin Oncol; 1996 May; 14(5):1552-7. PubMed ID: 8622071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
    Lorusso D; Mainenti S; Pietragalla A; Fusco E; Malaguti P; Masciullo V; Scambia G
    Oncology; 2011; 80(5-6):390-4. PubMed ID: 21829040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
    Verweij J; Lund B; Beijnen J; Planting A; de Boer-Dennert M; Koier I; Rosing H; Hansen H
    Ann Oncol; 1993 Sep; 4(8):673-8. PubMed ID: 8240998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
    Pazdur R; Diaz-Canton E; Ballard WP; Bradof JE; Graham S; Arbuck SG; Abbruzzese JL; Winn R
    J Clin Oncol; 1997 Aug; 15(8):2905-9. PubMed ID: 9256134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.
    Creemers GJ; Wanders J; Gamucci T; Vallentin S; Dirix LY; Schöffski P; Hudson I; Verweij J
    Ann Oncol; 1995 Oct; 6(8):844-6. PubMed ID: 8589027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of topotecan in malignant melanoma.
    Kraut EH; Walker MJ; Staubus A; Gochnour D; Balcerzak SP
    Cancer Invest; 1997; 15(4):318-20. PubMed ID: 9246152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193.
    Wolff AC; O'Neill A; Kennedy MJ; Stewart JA; Gradishar WJ; Lord RS; Davidson NE; Wood WC
    Clin Breast Cancer; 2005 Oct; 6(4):334-9. PubMed ID: 16277884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.